PEOPLE - Ixion (US) makes appointment:
This article was originally published in Clinica
Louis Kessler has been appointed vice-president of corporate development at Ixion of Alachua, Florida. Mr Kessler was previously director of intellectual properties and technology transfer at Univax Biologics/Nabi, a biopharmaceutical company. Ixion develops diagnostic and prevention options for oxalate-based disorders, such as kidney stones, primary hyperoxaluria, Crohn's Disease and cystic fibrosis.
You may also be interested in...
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.